PhaseV

🚀 Turning Uncertainty into Opportunity: Smarter Clinical Asset Evaluation with Causal Machine Learning 💡 Many promising drugs are abandoned too soon, often due to strategic shifts or a lack of deep data analysis. But what if we could rescue these assets and uncover hidden opportunities? In his latest article, PhaseV CEO Raviv Pryluk explores how causal ML is revolutionizing due diligence for investors and pharma companies by: 🔎 Identifying hidden value in overlooked assets 🔬 Analyzing patient-level data to uncover true treatment effects ⚠️ Detecting subtle safety signals that aggregate data might miss 📈 Predicting trial success and optimizing development paths With causal ML, investors can make smarter, data-driven decisions, minimizing uncertainty and maximizing returns - all while accelerating the path to new treatments. At PhaseV, we’re at the forefront of this revolution, empowering teams with the tools to de-risk investments and unlock the full potential of clinical assets. 📖 Read the full article in Applied Clinical Trials: https://lnkd.in/e-mTFavW #ClinicalTrials #CausalAI #MachineLearning #Biopharma #DrugDevelopment #PhaseV #AppliedClinicalTrials #Investment #PharmaInnovation #AI

Join us at ADMTP 2025 in Regensburg, Germany, on Feb 27! PhaseV CEO & Co-founder Raviv Pryluk and CTO & Co-founder Elad Berkman will share insights on clinical trial optimization and innovative trial designs. 📌 Session V (11:05 AM) – Elad Berkman 🔹 Exploratory Adaptive Enrichment Design with Sample Size Re-estimation: A Novel Approach for Clinical Trial Optimization 📌 Session VII (3:40 PM) – Raviv Pryluk 🔹 Model-Guided Parameter Optimization for Complex Innovative Trial Designs Don’t miss the chance to connect and explore groundbreaking approaches! See you there! #ADMTP2025 #ClinicalTrials #Innovation #AdaptiveDesign #Healthcare #AI #AgenticAI

I've been asked several times over the past few weeks: "Have you heard that the FDA proposed a framework to advance the credibility of AI models? Does PhaseV's platform align with this framework?" So...read my answer

We’re kicking off our 2025 Webinar Series with our first session broadcasting live on Thursday, March 6 at 1:00 PM EST | 10:00 AM PST | 7:00 PM CET! 🎥 Join us as we discuss new innovations in clinical development leveraging AI, real-world evidence, and predictive analytics. 🔹 Moderated by our very own Brad Carlin 🔹 Featuring speakers from Flatiron Health, AstraZeneca, and The University of Texas MD Anderson Cancer Center Don’t miss this opportunity to gain valuable insights that can help drive innovation in clinical development. 🔗 Register here: http://bit.ly/4hx0glI We look forward to seeing you there! #ClinicalDevelopment #AI #MachineLearning #RealWorldData #Predictive #Analytics #PatientSelection #Adaptive #Bayesian

If you are in the Boston area, come by the Drug R&D 2025 conference, where today at 1 PM our CEO Raviv Pryluk will present how AI drives precision, efficiency, and success in clinical trials https://d-rnd.com/

We’re thrilled to share our exciting partnership with Alimentiv [featured in Fierce Biotech]! By integrating PhaseV’s adaptive machine learning software with Alimentiv’s trial technology and GI expertise, we’re pushing the boundaries of clinical development—enhancing efficiency, optimizing decision-making, and ultimately accelerating innovation in GI-focused trials. A big thank you to our partners at Alimentiv for their collaboration and vision. Together, we’re making GI drug development more efficient, effective, and innovative! #ClinicalTrials #MachineLearning #HealthTech #Collaboration

Excited for our collaboration with University Health Network to appear alongside additional significant drug discovery and development deals powered by AI in Drug Discovery World. Even more excited to be able, together with University Health Network, to change the lives of Lupus patients around the world

Exciting insights from Dan Goldstaub, along with additional industry experts, on the role of tech, ML, and AI in drug development in 2025. Check out the latest expert predictions in Drug Discovery World and share what you anticipate as the most significant transformation in this field for the upcoming year

We are thrilled to announce our recent collaboration with University Health Network to improve development of treatments for Lupus. Combining our Casual-ML solutions with UHN's eniqe SLE expertise and registry will enable to better understand the factors driving heterogeneity in Lupus progression as well as treatment responses. These insights can power more precise and effective trials in the field, leading to better treatments for Lupus patients that need them.

Read what we have been up to in the past year, what is all the hype about, and what to expect in 2025 (spoiler: clinical development will not be the same!)